Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要